PL2887958T3 - Formulacje liposomowe - Google Patents
Formulacje liposomoweInfo
- Publication number
- PL2887958T3 PL2887958T3 PL13830622T PL13830622T PL2887958T3 PL 2887958 T3 PL2887958 T3 PL 2887958T3 PL 13830622 T PL13830622 T PL 13830622T PL 13830622 T PL13830622 T PL 13830622T PL 2887958 T3 PL2887958 T3 PL 2887958T3
- Authority
- PL
- Poland
- Prior art keywords
- liposome formulations
- liposome
- formulations
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
- A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/04—Drugs for disorders of the respiratory system for throat disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
- A61P5/16—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4 for decreasing, blocking or antagonising the activity of the thyroid hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Ophthalmology & Optometry (AREA)
- Diabetes (AREA)
- Immunology (AREA)
- Endocrinology (AREA)
- Pulmonology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Dermatology (AREA)
- Hematology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Dispersion Chemistry (AREA)
- Biomedical Technology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Urology & Nephrology (AREA)
- Obesity (AREA)
- Otolaryngology (AREA)
- Rheumatology (AREA)
- Neurology (AREA)
- Heart & Thoracic Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261691455P | 2012-08-21 | 2012-08-21 | |
| US201361791693P | 2013-03-15 | 2013-03-15 | |
| US201361862300P | 2013-08-05 | 2013-08-05 | |
| EP13830622.0A EP2887958B1 (en) | 2012-08-21 | 2013-08-15 | Liposome formulations |
| PCT/US2013/055084 WO2014031429A2 (en) | 2012-08-21 | 2013-08-15 | Liposome formulations |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL2887958T3 true PL2887958T3 (pl) | 2021-11-22 |
Family
ID=50150466
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL13830622T PL2887958T3 (pl) | 2012-08-21 | 2013-08-15 | Formulacje liposomowe |
Country Status (16)
| Country | Link |
|---|---|
| US (2) | US10548841B2 (pl) |
| EP (1) | EP2887958B1 (pl) |
| JP (3) | JP6336448B2 (pl) |
| KR (2) | KR102177437B1 (pl) |
| CN (1) | CN104582728A (pl) |
| AR (1) | AR092372A1 (pl) |
| BR (1) | BR112015003658B1 (pl) |
| CA (2) | CA3098856C (pl) |
| CL (1) | CL2015000418A1 (pl) |
| ES (1) | ES2881671T3 (pl) |
| HU (1) | HUE058912T2 (pl) |
| MX (2) | MX363822B (pl) |
| PL (1) | PL2887958T3 (pl) |
| RU (1) | RU2680096C2 (pl) |
| TW (2) | TWI608848B (pl) |
| WO (1) | WO2014031429A2 (pl) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112016000282A2 (pt) * | 2013-07-11 | 2017-12-12 | Novartis Ag | uso de antagonista de vegf em tratamento de retinopatia da prematuridade |
| MX2016005505A (es) * | 2013-12-19 | 2016-07-22 | Hoffmann La Roche | Modulador de la proteina de transferencia de ester de colesterilo (cetp) para usarse en el tratamiento de enfermedades oculares. |
| US20170056469A1 (en) * | 2014-05-02 | 2017-03-02 | Mayo Foundation For Medical Education And Research | Individualized treatment of eye disease |
| KR101778004B1 (ko) | 2015-06-22 | 2017-09-15 | (주) 에빅스젠 | 이마티닙을 유효성분으로 포함하는 안구 건조 질환 예방 및 치료용 약학 조성물 |
| WO2017083800A1 (en) * | 2015-11-13 | 2017-05-18 | Ohr Pharmaceutical, Inc. | Occult cnv size as a predictor for treatment with squalamine |
| WO2019154776A1 (en) * | 2018-02-06 | 2019-08-15 | F. Hoffmann-La Roche Ag | Treatment of ophthalmologic diseases |
| JP2021535206A (ja) * | 2018-08-23 | 2021-12-16 | バーンスタイン，エリック，エフ． | 皮膚状態を治療するために抗ｖｅｇｆ化合物を適用するためおよびこのような化合物を使用するためのシステム、デバイスおよび方法 |
| CN109180798B (zh) * | 2018-09-04 | 2020-10-27 | 武汉原生药谷生物医药科技有限公司 | 一种增强型治疗性抗体及其应用 |
| SG11202103064YA (en) | 2018-10-29 | 2021-05-28 | Hoffmann La Roche | Antibody formulation |
| WO2020190733A1 (en) * | 2019-03-15 | 2020-09-24 | University Of Rhode Island Board Of Trustees | pHLIP®-MEDIATED TARGETING OF CORTICOSTEROIDS TO DISEASED TISSUE |
| EP3968949A1 (en) | 2019-05-16 | 2022-03-23 | OPKO Pharmaceuticals, LLC | Triamcinolone acetonide-loaded liposomes topical ophthalmic formulations for prevention of macular thickening and its associated visual outcomes after lens surgery |
| MA54325A (fr) | 2019-06-05 | 2022-05-11 | Regeneron Pharma | Dispositifs et procédés pour l'administration précise de doses |
| CN113546172A (zh) * | 2020-04-24 | 2021-10-26 | 山东大学齐鲁医院 | Vegf抑制剂在制备治疗缺氧相关疾病药物中的应用 |
| MX2022015656A (es) * | 2020-06-15 | 2023-03-22 | Opko Pharmaceuticals Llc | Formulaciones oftalmaticas topicas de liposomas cargados con acetonido de triamcinolona como terapia primaria para el edema macular secundario a la oclusion de la vena retiniana de rama. |
| USD1120314S1 (en) | 2022-11-30 | 2026-03-24 | Regeneron Pharmaceuticals, Inc. | Dose delivery device |
| CN116585304B (zh) * | 2023-04-25 | 2024-04-05 | 四川大学华西医院 | 一种急性肝损伤保护药物及其制备方法 |
| WO2025146683A1 (en) | 2024-01-03 | 2025-07-10 | Lyotropic Delivery Systems Ltd. | Topical formulations for delivery of an active compound to the back of the eye |
| CN119701010B (zh) * | 2024-12-25 | 2025-10-28 | 山东第一医科大学附属眼科医院(山东省眼科医院) | 一种基于中性粒细胞纳米囊泡的抗炎和抗血管双向诱捕联合自发光动力的复合物及其制备方法和应用 |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6565861B1 (en) * | 2000-02-11 | 2003-05-20 | Isis Innovation Limited | Artificial tear formulation |
| US6610322B1 (en) * | 2000-12-20 | 2003-08-26 | Brian Charles Keller | Self forming, thermodynamically stable liposomes and their applications |
| US7785578B2 (en) * | 2002-10-11 | 2010-08-31 | Aciont, Inc. | Non-invasive ocular drug delivery |
| EP1643971A2 (en) * | 2003-05-22 | 2006-04-12 | Neopharm, Inc. | Liposomal formulations comprising a combination of two or more active agents |
| WO2007076274A2 (en) * | 2005-12-22 | 2007-07-05 | Bausch & Lomb Incorporated | Artificial tear solution containing poly (ethylene glycol) peg lipids |
| WO2007076454A1 (en) * | 2005-12-23 | 2007-07-05 | Alcon, Inc. | Pharmaceutical formulation for delivery of receptor tyrosine kinase inhibiting (rtki) compounds to the eye |
| WO2008063932A2 (en) * | 2006-11-10 | 2008-05-29 | Genentech, Inc. | Method for treating age-related macular degeneration |
| WO2008070740A1 (en) | 2006-12-07 | 2008-06-12 | F.Hoffmann-La Roche Ag | Phosphoinositide 3-kinase inhibitor compounds and methods of use |
| US8216571B2 (en) * | 2007-10-22 | 2012-07-10 | Schering Corporation | Fully human anti-VEGF antibodies and methods of using |
| US8887944B2 (en) * | 2007-12-11 | 2014-11-18 | Tokitae Llc | Temperature-stabilized storage systems configured for storage and stabilization of modular units |
| US8470792B2 (en) * | 2008-12-04 | 2013-06-25 | Opko Pharmaceuticals, Llc. | Compositions and methods for selective inhibition of VEGF |
| AU2010257181A1 (en) * | 2009-06-02 | 2012-01-12 | Brian Charles Keller | Pure PEG-lipid conjugates |
| WO2010141068A1 (en) * | 2009-06-02 | 2010-12-09 | Wu Nian | Opthalmic compositions of cyclosporin |
| US8956600B2 (en) * | 2009-08-10 | 2015-02-17 | Taiwan Liposome Co. Ltd. | Ophthalmic drug delivery system containing phospholipid and cholesterol |
| RU2595718C2 (ru) * | 2009-09-09 | 2016-08-27 | Селджен Авиломикс Рисерч,Инк. | Ингибиторы pi3-киназы и их применение |
-
2013
- 2013-08-15 ES ES13830622T patent/ES2881671T3/es active Active
- 2013-08-15 RU RU2015107317A patent/RU2680096C2/ru active
- 2013-08-15 PL PL13830622T patent/PL2887958T3/pl unknown
- 2013-08-15 WO PCT/US2013/055084 patent/WO2014031429A2/en not_active Ceased
- 2013-08-15 CA CA3098856A patent/CA3098856C/en active Active
- 2013-08-15 JP JP2015528536A patent/JP6336448B2/ja active Active
- 2013-08-15 BR BR112015003658-9A patent/BR112015003658B1/pt active IP Right Grant
- 2013-08-15 EP EP13830622.0A patent/EP2887958B1/en active Active
- 2013-08-15 KR KR1020207005268A patent/KR102177437B1/ko active Active
- 2013-08-15 CN CN201380044348.4A patent/CN104582728A/zh active Pending
- 2013-08-15 MX MX2015002233A patent/MX363822B/es active IP Right Grant
- 2013-08-15 KR KR1020157004549A patent/KR102083700B1/ko active Active
- 2013-08-15 US US14/422,587 patent/US10548841B2/en active Active
- 2013-08-15 HU HUE13830622A patent/HUE058912T2/hu unknown
- 2013-08-15 CA CA2879597A patent/CA2879597C/en active Active
- 2013-08-21 AR ARP130102960A patent/AR092372A1/es not_active Application Discontinuation
- 2013-08-22 TW TW102130093A patent/TWI608848B/zh active
- 2013-08-22 TW TW105114326A patent/TWI683675B/zh active
-
2015
- 2015-02-19 MX MX2019001021A patent/MX2019001021A/es unknown
- 2015-02-20 CL CL2015000418A patent/CL2015000418A1/es unknown
-
2018
- 2018-05-02 JP JP2018088574A patent/JP6680827B2/ja active Active
-
2019
- 2019-12-12 US US16/712,261 patent/US11712419B2/en active Active
-
2020
- 2020-03-17 JP JP2020046303A patent/JP7098674B2/ja active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HUE058912T2 (hu) | Liposzóma készítmények | |
| IL233530A0 (en) | cosmetic | |
| EP2701734A4 (en) | LIPOSOMAL FORMULATIONS | |
| ZA201509340B (en) | Proliposomal testosterone formulations | |
| SI2877155T1 (sl) | Opioidne formulacije | |
| PL2802209T3 (pl) | Preparaty do uszu | |
| IL289157A (en) | Opioid compounds | |
| SG11201504134SA (en) | External preparation | |
| EP2861218A4 (en) | LIPOSOME FORMULATIONS | |
| EP2821058A4 (en) | COSMETIC | |
| EP2821059A4 (en) | COSMETIC | |
| GB2500883B (en) | Improved saw-horse | |
| EP2662071A4 (en) | COSMETIC PRODUCT | |
| PL2908859T3 (pl) | Formulacje arypiprazolu | |
| GB201110278D0 (en) | Formulations | |
| GB201206178D0 (en) | Formulations | |
| GB201210088D0 (en) | Odontalgic preparation | |
| GB201211247D0 (en) | Improved formulation | |
| GB201111578D0 (en) | Pharmeutical formulations | |
| GB201107626D0 (en) | Formulations | |
| GB201111013D0 (en) | Formulations | |
| GB201105360D0 (en) | Formulations | |
| GB201102795D0 (en) | Formulations | |
| GB201104048D0 (en) | Formulations | |
| GB201107627D0 (en) | Formulations |